Industry Partnership | Collaborate with OCRA

Industry Partnerships

We partner with leading pharmaceutical, biotechnology, and diagnostic companies to support and strengthen OCRA's mission.

Why Partner with OCRA?

As the leading ovarian cancer organization in the world, we recognize that stakeholder collaboration is key to achieving our goal of curing gynecologic cancers and ensuring the development of safe, more effective therapies. We work with our partners to fulfill our shared goals of raising awareness, supporting patients, emphasizing education, and advancing critical research and treatment options.

Partnering with OCRA helps bring your clinical work full circle, supporting patients through every stage of their journeys. By collaborating with us, industry partners gain a better understanding of patient needs, helping ensure developments that address their concerns, while gaining an increased focus on real-world data.

Ways We Collaborate with Industry

We have a number of year-round sponsorship and support opportunities for partners, from patient support and education, to advocacy, to our International Conference, as well as our Gynecologic Cancer Collaborative. OCRA also engages with partners to increase awareness through unbranded communications campaigns and opportunities to elevate the patient voice in therapy development. Please contact us if you wish to learn more about our work and how we can partner to better serve and support the gynecologic cancer community.

At present, OCRA does not engage with partners for paid advertisements on our website or digital/print publications and newsletters. We do have opportunities for brand awareness and advertisements via our International Gynecologic Cancer Conference.

For more information, please contact Jessica Hughson-Andrade at jhughson-andrade@ocrahope.org 

Pharmaceutical Partners

Conflict of Interest Statement — Industry Partners

Corporate partners including industry do not shape OCRA’s agenda, research, or advocacy.
In 2023, industry partners represented 8% of OCRA’s overall revenue.
If an industry partner sponsors an OCRA program, grant, or educational materials, it is publicly acknowledged and the supporting company has no editorial or strategic input.
Any reference to a specific commercial product or service does not constitute or imply an endorsement by OCRA of the product or service or its producer or provider. The views and opinions expressed in any referenced document or on any referenced website do not necessarily reflect those of OCRA.

Read our conflict of interest policy